nach oben

Erschienen in:

01.11.2012 | CANCER

Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study

verfasst von: Paraskevi Panagopoulou, Helen Gogas, Nick Dessypris, Nikos Maniadakis, George Fountzilas, Eleni Th. Petridou

Erschienen in: European Journal of Epidemiology | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Apart from tumour, treatment and patient characteristics at diagnosis, access to healthcare delivery may as well play a significant role in breast cancer prognosis. This study aimed to assess the additional impact exerted on survival by travel burden—a surrogate indicator of limited access to healthcare- expressed as geographical distance and/or time needed to reach the tertiary healthcare center from the patient’s residence. Between 1997 and 2005, 2,789 women participated in therapeutic clinical trials conducted by the Hellenic Cooperative Oncology Group. The effect of geographical distance and travel time between patient’s residence and treating hospital on survival was estimated using Cox proportional hazards regression adjusting for age, menopausal status, tumour size/grade, positive nodes (number), hormonal receptor status, HER2 overexpression, surgery type/treatment protocol as well as for body mass index >30 kg/m². More aggressive tumour features, older treatment protocols and modifiable patient characteristics, such as obesity (HR: 1.27) adversely impacted on breast cancer survival. In addition, less studied indicators of access to healthcare, such as geographic distance >350 km and travel time >4 h were independently and significantly associated with worse outcomes (HR = 1.43 and 1.34 respectively). In conclusion, to address inequalities in breast cancer survival, improvements in access to healthcare services related to increased travel burden especially for patients of lower socioeconomic status should be considered, more than ever at times of financial crisis and independently of already known modifiable patient characteristics.

Nur mit Berechtigung zugänglich

Soerjomataram I, Louwman MWJ, Ribot JG, Roukema JA, Coebergh JWW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107(3):309–30.PubMedCrossRef

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106. doi:10.1016/S0140-6736(05)67887-7.PubMed

Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010;17(4):R245–62. doi:10.1677/erc-10-0136.PubMedCrossRef

Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol. 2006;17(10):1504–11. doi:10.1093/annonc/mdl147.PubMedCrossRef

Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, et al. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer. 2008;123(9):2188–94.PubMedCrossRef

Hellmann SS, Thygesen LC, Tolstrup JS, Gronbaek M. Modifiable risk factors and survival in women diagnosed with primary breast cancer: results from a prospective cohort study. Eur J Cancer Prevent. 2010;19(5):366–73. doi:10.1097/CEJ.0b013e32833b4828.CrossRef

Pierce JP, Stefanick ML, Flatt SW, Natarajan L, Sternfeld B, Madlensky L, et al. Greater Survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol. 2007;25(17):2345–51. doi:10.1200/jco.2006.08.6819.PubMedCrossRef

Parkin DM, Boyd L. Cancers attributable to overweight and obesity in the UK in 2010. Br J Cancer. 2011;105(S2):S34–7.PubMedCrossRef

Protani M, Coory M, Martin J. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627–35.PubMedCrossRef

10.

Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004;15(6):875–84. doi:10.1093/annonc/mdh222.PubMedCrossRef

11.

Barnett GC, Shah M, Redman K, Easton DF, Ponder BAJ, Pharoah PDP. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol. 2008;26(20):3310–6. doi:10.1200/jco.2006.10.3168.PubMedCrossRef

12.

Ewertz M, Jensen M-B, Gunnarsdóttir KÁ, Højris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2010;29(1):25–31. doi:10.1200/jco.2010.29.7614.PubMedCrossRef

13.

Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J, et al. General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1871–7. doi:10.1158/1055-9965.epi-06-0356.PubMedCrossRef

14.

Dignam JJ, Mamounas EP. Obesity and breast cancer prognosis: an expanding body of evidence. Ann Oncol. 2004;15(6):850–1. doi:10.1093/annonc/mdh241.PubMedCrossRef

15.

Bouchardy C, Verkooijen HM, Fioretta G. Social class is an important and independent prognostic factor of breast cancer mortality. Int J Cancer. 2006;119(5):1145–51.PubMedCrossRef

16.

Dalton SO, Ross L, Düring M, Carlsen K, Mortensen PB, Lynch J, et al. Influence of socioeconomic factors on survival after breast cancer—a nationwide cohort study of women diagnosed with breast cancer in Denmark 1983–1999. Int J Cancer. 2007;121(11):2524–31.PubMedCrossRef

17.

Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94(7):490–6. doi:10.1093/jnci/94.7.490.PubMedCrossRef

18.

Yu X. Socioeconomic disparities in breast cancer survival: relation to stage at diagnosis, treatment and race. BMC Cancer. 2009;9(1):364.PubMedCrossRef

19.

McGinnis JM, Williams-Russo P, Knickman JR. The case for more active policy attention to health promotion. Health Aff. 2002;21(2):78–93. doi:10.1377/hlthaff.21.2.78.CrossRef

20.

Probst J, Laditka S, Wang J-Y, Johnson A. Effects of residence and race on burden of travel for care: cross sectional analysis of the 2001 US National Household Travel Survey. BMC Health Services Res. 2007;7(1):40.CrossRef

21.

Zgibor JC, Gieraltowski LB, Talbott EO, Fabio A, Sharma RK, Karimi H. The association between driving distance and glycemic control in rural areas. J Diabetes Sci Technol. 2011;5(3):494–500.PubMed

22.

Scoggins JF, Fedorenko CR, Donahue SMA, Buchwald D, Blough DK, Ramsey SD. Is distance to provider a barrier to care for medicaid patients with breast, colorectal, or lung cancer? J Rural Health. 2011; Article first published online: 31 Mar 2011. doi:10.1111/j.1748-0361.2011.00371.x.

23.

Dejardin O, Remontet L, Bouvier AM, Danzon A, Tretarre B, Delafosse P, et al. Socioeconomic and geographic determinants of survival of patients with digestive cancer in France. Br J Cancer. 2006;95(7):944–9.PubMedCrossRef

24.

Crawford SM, Sauerzapf V, Haynes R, Zhao H, Forman D, Jones AP. Social and geographical factors affecting access to treatment of lung cancer. Br J Cancer. 2009;101(6):897–901.PubMedCrossRef

25.

Athas WF, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key CR. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst. 2000;92(3):269–71. doi:10.1093/jnci/92.3.269.PubMedCrossRef

26.

Jones AP, Haynes R, Sauerzapf V, Crawford SM, Zhao H, Forman D. Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer. 2008;44(7):992–9.PubMedCrossRef

27.

Baird G, Flynn R, Baxter G, Donnelly M, Lawrence J. Travel time and cancer care: an example of the inverse care law? Rural Remote Health. 2008;8(4):1003 (Online). Epub Nov 13, 2008.

28.

Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005;16(11):1762–71. doi:10.1093/annonc/mdi366.PubMedCrossRef

29.

Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol. 2008;19(5):853–60. doi:10.1093/annonc/mdm539.PubMedCrossRef

30.

Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, et al. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat. 2011;2011 Dec 21. [Epub ahead of print] doi:10.1007/s10549-011-1913-4.

31.

Papadimitriou CA, Papakostas P, Timotheadou E, Aravantinos G, Bamias A, Fountzilas G. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and Weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) Study. Cancer Invest. 2008;26(5):491–8. doi:10.1080/07357900701829785.PubMedCrossRef

32.

Fountzilas G, Pectasides D, Christodoulou C, Timotheadou E, Economopoulos T, Papakostas P, et al. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. Med Oncol. 2006;23(4):479–88.PubMedCrossRef

33.

Acock AC. Working with missing values. J Marriage Fam. 2005;67:1012–28.CrossRef

34.

Little RJA, Rubin DB. Statistical analysis with missing data. New York: Wiley; 1987.

35.

Meden T, St. John-Larkin C, Hermes D, Sommerschield S. Relationship between travel distance and utilization of breast cancer treatment in rural northern michigan. JAMA. 2002;287(1):111. doi:10.1001/jama.287.1.111.PubMedCrossRef

36.

Celaya M, Rees J, Gibson J, Riddle B, Greenberg E. Travel distance and season of diagnosis affect treatment choices for women with early-stage breast cancer in a predominantly rural population (United States). Cancer Causes Control. 2006;17(6):851–6.PubMedCrossRef

37.

Ahamad A. Geographic access to cancer care: a disparity and a solution. Postgrad Med J. 2011;87(1031):585–9. doi:10.1136/pgmj.2010.111930.PubMedCrossRef

38.

Wan Y. Examine the effect of geographic distance on breast cancer patients’ utilization of high volume hospitals [Master of Science Thesis]. Iowa. University of Iowa; 2009. http://ir.uiowa.edu/etd/446.

39.

Wee C, McCarthy E, Davis R, Phillips R. Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care? Ann Intern Med. 2000;132(9):697–704.PubMed

40.

Mitchell KJ, Fritschi L, Reid A, McEvoy SP, Ingram DM, Jamrozik K, et al. Rural-urban differences in the presentation, management and survival of breast cancer in Western Australia. Breast. 2006;15(6):769–76. doi:10.1016/j.breast.2006.04.001.PubMedCrossRef

41.

Gulliford M, Figueroa-Munoz J, Morgan M, Hughes D, Gibson B, Beech R, et al. What does ‘access to health care’ mean? J Health Serv Res Policy. 2002;7(3):186–8. doi:10.1258/135581902760082517.PubMedCrossRef

42.

OECD. Regions at a glance 2007. Regional disparities in GDP per capita. 2007. p. 58–3. Available from: www.sourceoecd.org/governance/9789264009875.

43.

Charalampopoulou A, Petridou E, Spyridopoulos T, Dessypris N, Oikonomou A, Athanasiadou-Piperopoulou F, et al. An integrated evaluation of socioeconomic and clinical factors in the survival from childhood acute lymphoblastic leukaemia: a study in Greece. Eur J Cancer Prev. 2004;13(5):397–401.PubMedCrossRef

44.

Lightfoot TJ, Johnston WT, Simpson J, Smith AG, Ansell P, Crouch S, et al. Survival from childhood acute lymphoblastic leukaemia: the impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48(2):263–9.PubMed

45.

Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009;18(6):883–93. doi:10.1089/jwh.2008.1127.CrossRef

46.

Loi S, Milne RL, Friedlander ML, McCredie MRE, Giles GG, Hopper JL, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1686–91. doi:10.1158/1055-9965.epi-05-0042.PubMedCrossRef

47.

Borugian MJ, Sheps SB, Kim-Sing C, Olivotto IA, Van Patten C, Dunn BP, et al. Waist-to-hip ratio and breast cancer mortality. Am J Epidemiol. 2003;158(10):963–8. doi:10.1093/aje/kwg236.PubMedCrossRef

48.

Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 2002;13(4):325–32.PubMedCrossRef

49.

Hall HI, Coates RJ, Uhler RJ, Brinton LA, Gammon MD, Brogan D, et al. Stage of breast cancer in relation to body mass index and bra cup size. Int J Cancer. 1999;82(1):23–7.PubMedCrossRef

50.

Griggs JJ, Sorbero MES, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165(11):1267–73. doi:10.1001/archinte.165.11.1267.PubMedCrossRef

51.

McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol. 2003;21(10):1961–6.PubMedCrossRef

52.

Maehle B, Tretli S. Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients. Breast Cancer Res Treat. 1996;41(2):123–30.PubMedCrossRef

53.

Sparano J, Wang M, Martino S, Jones V, Perez E, Saphner T, et al. editors [S2-1]. Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer. 33rd Annual San Antonio Breast Cancer Symposium; 2010; San Antonio, Texas, USA.

54.

Ademuyiwa FO, Groman A, O’Connor T, Ambrosone C, Watroba N, Edge SB. Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer. 2011;117(18):4132–40.PubMedCrossRef

55.

Parolin V, Fiorio E, Mercanti A, Riolfi M, Cetto GL, Surmacz E, et al. Impact of BMI on clinical outcome of HER2-positive breast cancer. J Clin Oncol. 2010;28:15s(suppl;abstr 1130).

56.

Goodwin PJ. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol. 2008;26(6):833–4. doi:10.1200/jco.2007.14.7132.PubMedCrossRef

57.

Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-i, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101(1):48–60. doi:10.1093/jnci/djn415.PubMedCrossRef

58.

Kentikelenis A, Karanikolos M, Papanicolas I, Basu S, McKee M, Stuckler D. Health effects of financial crisis: omens of a Greek tragedy. Lancet. 2011;378(9801):1457–8.PubMedCrossRef

Titel: Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study
verfasst von: Paraskevi Panagopoulou
Helen Gogas
Nick Dessypris
Nikos Maniadakis
George Fountzilas
Eleni Th. Petridou
Publikationsdatum: 01.11.2012
Verlag: Springer Netherlands
Erschienen in: European Journal of Epidemiology / Ausgabe 11/2012
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-012-9737-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2012

Mortality among participants and non-participants in a prospective cohort study

Next frontiers in the genetic epidemiology of Alzheimer’s disease

Erratum to: The IEA-EEF European Congress of Epidemiology 2012: Epidemiology for a Fair and Healthy Society

Sex-related differences in prognosis after myocardial infarction: changes from 1978 to 2007

Publication biases in probiotics

Socioeconomic inequalities in homicide mortality: a population-based comparative study of 12 European countries